India Pharma Outlook Team | Thursday, 18 September 2025
ZyVet Animal Health, a part of Zydus Pharmaceuticals (USA), and the leader in affordable generic animal medicines, has just announced the debut of the first FDA-approved generic phenylpropanolamine hydrochloride tablets. This widely trusted therapy is the first choice to treat urinary incontinence in dogs, which is the main cause of sphincter hypotonus urethra, a condition that is often found in spayed females and senile pets.
The step toward a generic version of this drug is really a big step toward more accessible and less costly veterinary treatment. Presented there are available in different strengths, ZyVet's product guarantees the correct dosage and provides the necessary safety, thus supporting both veterinarians and pet owners in the control of a disease that affects not only the health of pets but also the quality of life of the family.
Punit Patel, President, and CEO of Zydus Americas, said on the occasion of the release, “Urinary incontinence is at the root of the health problems of pets and their families. Our phenylpropanolamine hydrochloride tablets are just the solution: they bring to the table clinical reliability at a very reasonable price, thus, allowing the vets to treat more patients. at no additional cost. This sends a very strong message that we at Zydus are firm believers that technology and accessibility can very well co-exist.”
Also Read: Cadila Pharma Launches Nu Nutridac Capsule for Anxiety Care
Generic drugs for animals approved by the FDA form less than 20% of the total portfolio. ZyVet is working on increasing the number of drugs available in generic form, thus filling the gap in the veterinary sector.
